€10.30
Your prediction
Financial data and news for Intellia
sharewise wants to provide you with the best news and tools for Intellia, so we directly link to the best financial data sources.
Financials
News
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?
Cathie Wood, the CEO of the investment management firm Ark Invest, is known for focusing on companies with significant innovative potential. One of her firm's picks, Intellia Therapeutics (NASDAQ:
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood seems to always be making market moves. The founder and CEO of Ark Invest publishes her transactions at the end of every trading day, and that gives us all a great way to track one of
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?
Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes biotechs that specialize in gene editing, a group of techniques that could
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares
On Jan. 5, John M. Leonard, the president and CEO of Intellia Therapeutics (NASDAQ:NTLA), executed an open-market sale of 34,146 directly held shares, totaling $314,484.66, as disclosed in a SEC
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street
Intellia Therapeutics (NASDAQ: NTLA) and Iovance Biotherapeutics (NASDAQ: IOVA) are relatively innovative biotech companies. However, due to company-specific headwinds, both have seen their shares
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
The "Magnificent Seven" stocks, a group of (mostly) tech giants, are among the most covered companies on Wall Street. The general sentiment about these corporations is that they boast attractive
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%
Intellia Therapeutics (NASDAQ: NTLA), a small-cap biotech company, has some notable bulls. One of them is Cathie Wood, the CEO of Ark Invest. The innovation-focused investment firm has long held
1 Stock Up by 63% This Year That Could Double, According to Wall Street
Shares of Intellia Therapeutics (NASDAQ: NTLA), a small-cap biotech company, are up by 63% this year. The company is benefiting from substantial clinical progress, and judging by price targets set